M&A Deal Summary |
|
|---|---|
| Date | 2022-07-11 |
| Target | La Jolla Pharmaceutical |
| Sector | Life Science |
| Buyer(s) | Innoviva |
| Deal Type | Add-on Acquisition |
| Deal Value | 149M USD |
| Advisor(s) | Cowen (Financial) Gibson, Dunn & Crutcher (Legal) |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1996 |
| Sector | Life Science |
| Employees | 112 |
| Revenue | 359M USD (2024) |
Innoviva is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. It is focused on the discovery, development, and commercialization of small-molecule medicines across several therapeutic areas, including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. Innoviva was founded in 1996 and is based in Burlingame, California.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Life Science M&A | 2 of 2 |
| Type: Add-on Acquisition M&A Deals | 2 of 2 |
| State: Massachusetts M&A | 2 of 2 |
| Country: United States M&A | 2 of 2 |
| Year: 2022 M&A | 2 of 2 |
| Size (of disclosed) | 1 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-05-23 |
Entasis Therapeutics
Waltham, Massachusetts, United States Entasis Therapeutics is an advanced late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted antibacterial products that address high unmet medical needs to treat serious infections caused by multidrug-resistant pathogens. Entasis Therapeutics was founded in 2015 and is based in Waltham, Massachusetts. |
Buy | $113M |
